EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Neuroprotective Role of Formononetin in a Scopolamine-Induced Alzheimer’s Disease Mouse Model

Akshay Sahani, Puja, Diksha Dalal, Anish Singh

Letters in Applied NanoBioScience · 30.06.2026 · 15 (2)

DOI: 10.33263/lianbs152.070 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Letters in Applied NanoBioScience, online erschienen am 30.06.2026. Verfasst von Akshay Sahani und 3 weiteren Autor:innen. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The progressive neurodegenerative illness known as Alzheimer's disease (AD) is typified by memory loss, cognitive decline, and neural malfunction. A common tool for creating experimental models of cognitive impairments resembling AD is scopolamine, a muscarinic receptor antagonist. Because of flavonoids’ anti-inflammatory, antioxidant, and neuroprotective qualities, the hunt for natural neuroprotective drugs has accelerated in recent years. This study investigated the neuroprotective effects of formononetin (10, 20, and 30 mg/kg; p.o) in a scopolamine-induced AD model. It examined its impact on oxidative stress indicators and cognitive performance. Scopolamine (1 mg/kg; i.p), administered for 3 days, significantly impaired memory and locomotor activity. Memory and learning capacities were assessed using behavioral tests such as the Open Field Test and the Y-maze Test. The findings revealed that pretreatment with formononetin, at a dosage of 30 mg/kg, significantly mitigated the behavioral changes induced by scopolamine. Formononetin improved memory, as evidenced by a higher percentage of spontaneous alterations in the Y-maze test. Additionally, it enhanced locomotor activity, as indicated by a higher square-crossing count in the OFT. Biochemical analysis showed that scopolamine therapy elevated TBARS levels and reduced GSH levels in the brain. In contrast, formononetin restored approximately 95% of GSH levels and reduced TBARS levels by 95%. The present study aims to investigate the neuroprotective efficacy of formononetin against scopolamine-induced cognitive and biochemical impairments that mimic AD pathology.

Zitieren

APA

Sahani, A., Puja, Dalal, D., & Singh, A. (2026). Neuroprotective Role of Formononetin in a Scopolamine-Induced Alzheimer’s Disease Mouse Model. Letters in Applied NanoBioScience, 15(2). https://doi.org/10.33263/lianbs152.070

Vancouver

Sahani A, Puja, Dalal D, Singh A. Neuroprotective Role of Formononetin in a Scopolamine-Induced Alzheimer’s Disease Mouse Model. Letters in Applied NanoBioScience. 2026;15(2). doi:10.33263/lianbs152.070

BibTeX
@article{Sahani2026,
  author = {Sahani, Akshay and Puja and Dalal, Diksha and Singh, Anish},
  title = {Neuroprotective Role of Formononetin in a Scopolamine-Induced Alzheimer’s Disease Mouse Model},
  journal = {Letters in Applied NanoBioScience},
  year = {2026},
  volume = {15},
  number = {2},
  doi = {10.33263/lianbs152.070}
}
Kostenlos starten →